LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 2154.3% from a year ago
Cash & equivalents stood at $320.68M at the end of Q1 FY2026, up 2154.3% from a year earlier and up 28.2% from the prior quarter. Over 3 fiscal years it compounded at +126.9% a year.
Context
- Cash & equivalents amounted to 81.5% of total assets at the end of Q1 FY2026, up 7.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +2154.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 250.17M USD
- Year-over-year change
- +988.8%
- 3-year CAGR
- +126.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 250.17M | +988.8% |
| FY2024 | 2024-12-31 | 22.98M | +53.4% |
| FY2023 | 2023-12-31 | 14.98M | -30.0% |
| FY2022 | 2022-12-31 | 21.4M | — |
Cash & Equivalents vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 cash & equivalents of $320.68M is the 3rd highest of the 10 companies compared; the peer median is $241.15M.
- Its year-over-year change of +2154.3% is the 2nd highest of 10, against a peer median of +42.7%.
- Cash & equivalents amounts to 81.5% of total assets for LBRX, versus a peer median of 25.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $24.65B | +161575.2% | +31.6% | 25.9% | |
| Sep 2026 | $976.45M | +278.5% | +15.7% | 54.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $320.68M | +2154.3% | +126.9% | 81.5% |
| Mar 2026 | $263.76M | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $242.65M | -0.9% | +14.1% | 88.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $241.15M | +1108.2% | +22.0% | 22.4% |
| Jun 2026 | $201.53M | +42.7% | -2.0% | 17.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M | +15.9% | -8.8% | 95.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M | +35.5% | +19.1% | 15.7% |
| Mar 2026 | $55.71M | +11.1% | +19.1% | 13.3% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $241.15M | +42.7% | +19.1% | 25.9% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.